CANDONI, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.309
EU - Europa 2.467
AS - Asia 1.358
SA - Sud America 21
AF - Africa 11
OC - Oceania 9
Continente sconosciuto - Info sul continente non disponibili 7
Totale 7.182
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.298
IT - Italia 771
GB - Regno Unito 672
HK - Hong Kong 448
CN - Cina 338
SG - Singapore 334
SE - Svezia 296
DE - Germania 175
FI - Finlandia 135
LT - Lituania 118
ID - Indonesia 84
UA - Ucraina 76
TR - Turchia 64
IE - Irlanda 47
BG - Bulgaria 34
CZ - Repubblica Ceca 25
NL - Olanda 24
IN - India 23
JP - Giappone 23
FR - Francia 22
VN - Vietnam 16
BR - Brasile 15
RU - Federazione Russa 15
AU - Australia 9
CA - Canada 9
CH - Svizzera 8
ES - Italia 8
TW - Taiwan 7
BE - Belgio 6
EU - Europa 6
HU - Ungheria 6
IQ - Iraq 6
PT - Portogallo 6
RO - Romania 6
TH - Thailandia 6
AR - Argentina 5
HR - Croazia 5
EG - Egitto 4
GR - Grecia 4
PL - Polonia 4
ZA - Sudafrica 4
PK - Pakistan 3
BA - Bosnia-Erzegovina 2
KR - Corea 2
LY - Libia 2
SA - Arabia Saudita 2
A2 - ???statistics.table.value.countryCode.A2??? 1
BZ - Belize 1
CL - Cile 1
LV - Lettonia 1
NO - Norvegia 1
PA - Panama 1
PH - Filippine 1
SY - Repubblica araba siriana 1
UG - Uganda 1
Totale 7.182
Salva come PNG Salva come JPEG
Città #
Fairfield 511
Ashburn 415
Southend 381
Hong Kong 372
Singapore 268
Woodbridge 260
Houston 255
Seattle 207
Chandler 195
Nyköping 191
Ann Arbor 158
Wilmington 156
Cambridge 152
Jacksonville 127
Dearborn 112
London 109
Beijing 100
Helsinki 100
Jakarta 76
Milan 67
Rome 60
San Diego 60
New York 52
Modena 51
Dublin 47
Princeton 40
Munich 38
Bologna 35
Washington 35
Sofia 34
Izmir 32
Kilburn 30
Eugene 29
Shanghai 26
Amsterdam 23
Dallas 23
Chiswick 21
Hounslow 19
Brno 17
Des Moines 17
Frankfurt am Main 17
Assago 16
Boardman 15
Florence 15
Casale sul Sile 14
Los Angeles 13
Falls Church 12
Guangzhou 12
Lanzhou 12
Phoenix 12
Prescot 12
Verona 12
Dong Ket 10
Lappeenranta 10
Bremen 9
Fremont 9
Islington 9
Redwood City 9
Reggio Emilia 9
Forlimpopoli 8
Mumbai 8
Pavia 8
Romola 8
Southwark 8
Bandung 7
Palermo 7
Wandsworth 7
Wuhan 7
Ancona 6
Ankara 6
Bangkok 6
Bari 6
Bergamo 6
Brussels 6
Chicago 6
Granada 6
Norwalk 6
Padova 6
Parma 6
São Paulo 6
Trento 6
Turin 6
Zurich 6
Acton 5
Alessandria 5
Cavle 5
Genoa 5
Ho Chi Minh City 5
San Jose 5
Toronto 5
Venice 5
Baghdad 4
Cairo 4
Jinan 4
Kobe 4
Kunming 4
Nanjing 4
Philadelphia 4
Pune 4
Rimini 4
Totale 5.362
Salva come PNG Salva come JPEG
Nome #
Characterization of Specific Immune Responses to Different Aspergillus Antigens during the Course of Invasive Aspergillosis in Hematologic Patients 259
Mucorales-specific T cells in patients with hematologic malignancies 201
Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010-a multicenter study) 195
A hematology consensus agreement on antifungal strategies for neutropenic patients with hematological malignancies and stem cell transplant recipients. 181
invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry study. 175
Variability of Voriconazole Trough Levels in Haematological Patients: Influence of Comedications with cytochrome P450(CYP) Inhibitors and/or with CYP Inhibitors plus CYP Inducers 172
Mucorles-specific T cells emerge in the course of invasive mucormucosis and may be used as a surrogate diagnostic marker in high-risk patients 167
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. 156
Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: a report from the SEIFEM and FUNGISCOPE registries. 152
All-trans retinoic acid (ATRA) in patients with chronic myeloid leukemia in the chronic phase. 151
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric-like GIMEMA LAL-1308 trial 150
Risk stratification for invasive fungal infections in patients with hematological malignancies: SEIFEM recommendations 149
Anagrelide in Essential Thrombocythemia: A Retrospective Analysis of 220 Patients. Session Type: Poster Session 646-III 145
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 142
Peg Interferon alpha-2b (Peg Intron) in Essential Thrombocythemia 140
Adherence to international guidelines for the treatment of invasive aspergillosis in acute myeloid leukaemia: Feasibility and utility (SEIFEM-2008B study) 139
PEG Intron in Essential Thrombocythemia: Two Years Treatment in 90 Patients. 136
Identification and characterization of Aspergillus-specific immune responses to diagnose invasive aspergillosis in high risk patients: a multicenter study 135
Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use 135
SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy 134
Evaluation of the practice of antifungal prophylaxis use in patients with newly diagnosed acute myeloid leukemia: results from the SEIFEM 2010-B registry. 132
Breakthrough invasive fungal diseases in acute myeloid leukemia patients receiving mould active triazole primary prophylaxis after intensive chemotherapy: An Italian consensus agreement on definitions and management 128
PEG Intron Treatment in 90 Patients with Essential Thrombocythemia (ET) Final Report of a Phase II Study. 127
Bone marrow biopsy and aspirate evaluation in 90 patients with Essential Thrombocythemia treated with PEG interferon alpha-2b. Preliminary results 127
Prospective multicenter study on infectious complications and clinical outcome of 230 unfit acute myeloid leukemia patients receiving first-line therapy with hypomethylating agents alone or in combination with Venetoclax 116
Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS) 115
Bone Marrow Evaluation According to the PVSG and WHO Criteria in 90 Essential Thrombocythemia (ET) Patients Treated with PEG Interferon alpha-2b. Preliminary Results. 113
Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry 109
PEG Interferon alpha2b (PEG Intron) in Essential Thrombocytemia: Phase II Study for Determination of the Minimun Effective, Safe and Tolerated Dose. Preliminary Data. 102
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia 100
PEG Interferon a-2b (PEG-Intron) in Essential Thrombocythemia: Phase II Study for Determination of the Minimum Effective, Safe and Tolerated Dose. Preliminary Data. 86
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemia 71
Prognostic Relevance of Multi-Antigenic Myeloma-Specific T-Cell Assay in Patients with Monoclonal Gammopathies 59
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study 59
'Real-life' analysis of the role of antifungal prophylaxis in preventing invasive aspergillosis in AML patients undergoing consolidation therapy: Sorveglianza Epidemiologica Infezioni nelle Emopatie (SEIFEM) 2016 study 53
COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies 52
In Ph+BCR-ABL1P210+ acute lymphoblastic leukemia the e13a2 (B2A2) transcript is prevalent 47
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 44
Fatigue in newly diagnosed acute myeloid leukaemia: General population comparison and predictive factors 42
Invasive aspergillosis in relapsed/refractory acute myeloid leukaemia patients: Results from SEIFEM 2016-B survey 41
Multicenter Observational Retrospective Study on Febrile Events in Patients with Acute Myeloid Leukemia Treated with Cpx-351 in "Real-Life": The SEIFEM Experience 31
FLAI induction regimen in elderly patients with acute myeloid leukemia 30
Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID-19: The GIMEMA EMATO-0321 study 30
ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol 29
Early palliative care versus usual haematological care in multiple myeloma: retrospective cohort study 28
Preclinical Validation of an Advanced Therapy Medicinal Product Based on Cytotoxic T Lymphocytes Specific for Mutated Nucleophosmin (NPM1mut) for the Treatment of NPM1mut-Acute Myeloid Leukemia 27
The Role of Wilms’ Tumor Gene (WT1) Expression as a Marker of Minimal Residual Disease in Acute Myeloid Leukemia 26
Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GINEMA infection program 26
Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) 25
Characteristics and clinical behavior of acute myeloid leukemia harboring rare non-A/B/D nucleophosmin (NPM1) gene mutation subtypes: a single-center experience and review of the literature 24
Intravascular lymphoma: Clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant' 23
The baseline comorbidity burden affects survival in elderly patients with acute myeloid leukemia receiving hypomethylating agents: Results from a multicentric clinical study 22
Antibody response to mRNA vaccination for COVID-19 in patients with AML receiving hypomethylating agents alone or with venetoclax 22
Monitoring by quantitative rt-pcr of ph+ cell mobilization induced by granulocyte colonystimulating factor (g-csf) in chronic myeloid leukemia 21
Clinical outcome of myeloid sarcoma in adult patients and effect of allogeneic stem cell transplantation. Results from a multicenter survey 21
Anti-CD20 therapy for chronic lymphocytic leukemia-associated autoimmune diseases 21
SARS-CoV-2 infection and vaccination in patients with hairy-cell leukaemia 20
Advanced mast cell disease: An Italian Hematological Multicenter experience 20
Bloodstream infections due to Gram-negative bacteria in patients with hematologic malignancies: updated epidemiology and risk factors for multidrug-resistant strains in an Italian perspective survey 20
Effect of prophylactic or pre-emptive use of tyrosine kinase inhibitors post-Allo SCT in bcr-abl positive acute lymphoblastic leukemia: a subanalysis of GITMO ph-positive ALL study 20
Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study 20
Candidaemia in haematological malignancy patients from a SEIFEM study: Epidemiological patterns according to antifungal prophylaxis 20
Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes 19
P-glycoprotein (PGP), and not lung resistance-related protein (LRP), is a negative prognostic factor in secondary leukemias 19
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front-line with paediatric-inspired regimens: A retrospective multicentre Campus ALL study 19
COVID-19 omicron variant outbreak in a hematopoietic stem cell transplant unit 19
Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias 18
Efficacy and safety of venetoclax plus hypomethylating agents in relapsed/refractory acute myeloid leukemia: a multicenter real-life experience 18
Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma 18
10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial 18
Neurological complications in adult allogeneic hematopoietic stem cell transplant patients: Incidence, characteristics and long-term follow-up in a multicenter series 18
A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study 18
18F-FDG Positron Emission Tomography (PET) Scan as a Useful Tool to Assess Response to Antimycotic Therapy in Disseminated Invasive Mycosis in Acute Myeloid Leukemia 18
Pneumocystis jirovecii pneumonia at chest High-resolution Computed Tomography (HRCT)in non-HIV immunocompromised patients: Spectrum of findings and mimickers 18
A 2024 Update on Menin Inhibitors. A New Class of Target Agents against KMT2A-Rearranged and NPM1-Mutated Acute Myeloid Leukemia 18
Antifungal prophylaxis with posaconazole in patients with acute myeloid leukemia: Dose intensification coupled with avoidance of proton pump inhibitors is beneficial in shortening time to effective concentrations 17
High-resolution Nanopore methylome-maps reveal random hyper-methylation at CpG-poor regions as driver of chemoresistance in leukemias 17
Monitoring of minimal residual disease by quantitative WT1 gene expression following reduced intensity conditioning allogeneic stem cell transplantation in acute myeloid leukemia 17
INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph1 acute lymphoblastic leukemia 17
FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience 17
Infections in patients with lymphoproliferative diseases treated with brentuximab vedotin: SEIFEM multicentric retrospective study 16
Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial 16
High Incidence of Invasive Fungal Diseases in Patients with FLT3-Mutated AML Treated with Midostaurin: Results of a Multicenter Observational SEIFEM Study 16
Autologus stem cell transplantation as postremission therapy for acute myeloid leukemia. Risk factors at diagnosis can predict the outcome [3] 15
High prognostic value of pre-allogeneic stem cell transplantation minimal residual disease detection by WT1 gene expression in AML transplanted in cytologic complete remission 15
GEMTUZUMAB OZOGAMICIN COMBINED WITH INDUCTION CHEMOTHERAPY IN YOUNG ADULTS WITH ACUTE MYELOID LEUKEMIA: REVIEW AND PERSPECTIVES. 15
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: Retrospective analysis of 530 patients 15
Acute myeloid leukemia in patients previously diagnosed with breast cancer: Experience of the GIMEMA group 15
Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors: A Registry-Based Study of the Italian Blood and Marrow Transplantation Society (GITMO) 15
Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression 15
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: A retrospective study from the Acute Leukemia Working Party of the EBMT 15
Progressive Multifocal Leukoencephalopathy in B-CLL Successfully Treated with Venetoclax and Pembrolizumab 15
Reduced prophylactic effect of tixagevimab-cilgavimab in patients with hematological malignancies and without antibody response after SARS-COV-2 vaccination 15
Pulmonary actinomycosis by Actinomyces graevenitzii in two hematologic patients 15
Fludarabine and cytosine-arabinoside for poor-risk acute myeloid leukemia 15
Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma 15
Gene expression profile predicts response to the combination of tosedostat and low-dose cytarabine in elderly AML 15
CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program 14
Prevalence and Prognostic Role of IDH Mutations in Acute Myeloid Leukemia: Results of the GIMEMA AML1516 Protocol 14
Mucormycosis in hematologic patients 14
Totale 6.086
Salva come PNG Salva come JPEG
Categoria #
all - tutte 96.914
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 96.914
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020794 0 0 0 61 98 140 160 109 91 52 47 36
2020/2021891 58 33 42 137 103 62 50 114 28 145 63 56
2021/2022729 38 101 59 44 30 57 34 42 87 52 90 95
2022/20231.245 79 47 43 53 88 87 319 130 200 28 72 99
2023/20242.253 58 67 144 201 370 187 325 230 54 65 223 329
2024/2025544 218 117 96 113 0 0 0 0 0 0 0 0
Totale 7.513